# DESCRIPTION

## STATEMENT OF GOVERNMENTAL INTEREST

- disclose government support

## BACKGROUND

- introduce muscular dystrophies
- limitations of animal models
- motivate human muscle model
- summarize previous studies

## SUMMARY

- summarize discovery
- introduce NMES
- outline method for treating muscle disorder
- describe graft creation
- introduce non-human animal model
- outline method for producing animal model

## DETAILED DESCRIPTION

- introduce patent application and its purpose
- provide background information and context
- outline structure of the patent application

### 1. DEFINITIONS

- define singular forms
- define "or" and "and/or"
- define "animal," "patient," or "subject"
- define "muscle disorder"
- define "muscle cells"
- define "muscle fiber" or "myofiber"
- define "myoblasts"
- define "myocytes"
- define "myofibrils"
- define "myotubes"
- define "xenograft" or "xenotransplant"
- define "xenotransplantation"
- define "disease model"
- define "drug screening"
- define "engrafting" or "engraftment"
- define "subject" and "individual"
- define "non-human animals" and "non-human mammals"
- define "tissue" and "tissue-specific"
- define "enhance", "growth", "injury", "regenerate", "stimulate", and "therapeutic amount"

### 2. OVERVIEW

- introduce need for animal models of human myopathies and muscular dystrophies
- describe applicant's discovery of methods to promote engraftment and development of myogenic cells
- outline purpose of methods and non-human models
- introduce FIG. 11, a flow chart of an example method
- describe step 1101, identifying and selecting an immunocompromised subject
- describe subsequent steps in the method, including irradiation, toxin injection, cell injection, and electrical stimulation

### 3. EXAMPLE EMBODIMENTS

- introduce NOD-Rag mice
- describe X-ray irradiation procedure
- explain cardiotoxin injection
- prepare human myoblasts for transplantation
- describe cell culture conditions
- determine myogenic purity of cell cultures
- prepare cells for injection
- inject cells into TA muscle compartment
- describe bioluminescence imaging procedure
- inject D-Luciferin solution
- acquire bioluminescence images
- quantify luciferase-mediated light intensity
- describe neuromuscular electrical stimulation protocol
- stimulate ankle dorsiflexors
- describe in vivo assessment of contractile function
- measure maximal torque generated by ankle dorsiflexors
- describe histology and immunofluorescence labeling
- prepare cryosections
- label sarcolemma and nuclear lamina
- label desmin
- detect neuromuscular junction formation
- detect presynaptic terminals
- detect matrix collagens
- reduce non-specific staining
- visualize primary antibodies
- mount sections
- view sections using confocal microscope
- count myofibers of human origin
- determine size of human myofibers
- measure distances between myofibers
- perform statistical analysis
- introduce bioluminescence imaging
- evaluate engraftment efficiency
- quantify survival of engrafted cells
- illustrate bioluminescent images
- show luminometric measurements
- indicate long-term survival of engrafted cells
- introduce torque and force measurements
- investigate contractile function
- compare contractile force
- introduce immunohistological analysis
- characterize engrafted muscle tissues
- compare mass of engrafted muscle
- characterize myofibers of human origin
- illustrate myofibers of human origin
- quantify number of fibers
- compare number of fibers
- illustrate sizes of myofibers
- compare sizes of myofibers
- illustrate distances between myofibers
- compare distances between myofibers
- introduce presence of collagen
- examine connective tissue
- illustrate collagenous materials
- compare collagenous materials
- introduce differentiation of fibers
- illustrate desmin in myoplasm
- illustrate central nuclei in fibers
- examine peripheral myonuclei
- test for innervation
- illustrate postsynaptic membrane
- examine presynaptic structures
- assess murine contamination

### 4. OTHER EMBODIMENTS

- identify subject with muscle disorder
- use hMSCs to regenerate muscle tissue
- inject hMPCs into limb portion
- inject hMPCs at different times and doses
- administer electrical stimulation
- use NMES to promote engraftment
- render subject incapable of rejecting hMPCs
- treat engrafted limbs with drugs or hormones
- generate mature human muscle fibers in vivo
- remove non-human muscle and prevent regeneration
- inject human myogenic cells into limb
- subject peroneal nerve to electrical stimulation
- use NMES to promote muscle differentiation
- administer NMES intermittently
- eliminate TA muscle by irradiation or toxin
- inject toxin to induce paralysis
- apply therapeutic electrical stimulation
- treat muscle disease FSHD
- create xenografts of human muscle tissue
- use immunodeficient mice for engraftment
- track human myoblasts with luciferase or GFP
- promote myogenesis with pharmacological agents
- study pathogenic mechanisms of muscular dystrophies
- develop mouse model for FSHD
- reproduce features of FSHD muscle
- construct muscle tissue from patient-derived cells
- introduce hMPCs from FSHD patient into mice
- develop muscle fibers of human origin
- express genes typical of FSHD tissue
- test usefulness of xenografts in mimicking disease
- create xenografts of hMPCs from diseased tissue
- express DUX4 and downstream genes
- optimize xenografting conditions for FSHD
- test therapies to treat FSHD
- provide method for producing non-human animal modeling human muscular disease
- obtain non-human animal and irradiate hindlimb with X-rays
- extract and degenerate TA muscle
- inject HMPCs or LHCN cells into TA muscle compartment
- stimulate peroneal nerve and assess contractile function
- compare graft with cells from non-diseased muscle
- screen for therapeutic drugs
- use animal model as in vivo humanized model of muscular disease
- assess drug toxicity on human muscle tissue
- use immunodeficient animal for implanting hMPC cells
- harvest and assess human muscle tissue
- transduce LHCN cells or hMPCs with retrovirus
- detect label expression
- assess effect of agent on in vivo humanized model
- screen for agents alleviating injury
- assess muscle recuperation
- use in vivo humanized model to assess agents
- select agent from group of chemical, small molecule, etc.
- administer agent to in vivo humanized model
- administer agent locally or systemically
- use pharmacological applicable carrier
- apply agent to media comprising LHCN cells or hMPCs
- introduce nucleic acid sequence into cell
- define environmental stimuli
- determine myotropism of viruses for gene therapy
- assess effects of drugs, antibodies, microorganisms, and toxins
- develop new approaches to treating human diseases of muscle
- transfer and insert new genetic information into cells
- introduce foreign genes into cells using various techniques
- identify muscle tissue with hereditary muscle disease
- insert gene into hMPCs to replace mutated or missing gene
- provide pharmaceutical compositions and kits comprising them

